Opioid effectiveness, addiction, and depression in chronic pain

Advances in Psychosomatic Medicine

Volumn 25, Issue , 2006, Pages 123-137

  Christo, Paul J ^a   Grabow, Theodore S ^a   Raja, Srinivasa N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

CHRONIC DISEASE; COGNITIVE THERAPY; DEPRESSION; HUMAN; METHODOLOGY; PAIN; REVIEW; TREATMENT OUTCOME;

ANALGESICS, OPIOID; CHRONIC DISEASE; COGNITIVE THERAPY; DEPRESSION; HUMANS; PAIN; TREATMENT OUTCOME;

EID: 4544276317     PISSN: 00653268     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000095370     Document Type: Article

References (76)

1. Brookoff D: Chronic pain: A new disease? Hosp Pract 2000;7:1-18.
2. Gutstein HB, Akil H: Opioid analgesics; in Hardman JG, Limbird LL (eds): Goodman and Oilman's The Pharmacological Basis of Therapeutics, ed 10. New York, McGraw-Hill, 2001, pp 569-619.
3. Foley KM: Problems of overarching importance, which transcend organ systems; in Bennett JC, Plum F (eds): Cecil Textbook of Medicine. Philadelphia, Saunders, 1996, pp 100-107.
4. American Pain Society: Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, ed 4. Glenview, IL, Am Pain Soc, 1999.
5. Portenoy RK, Foley KM, Inturrisi CE: The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions. Pain 1990;43: 273-286.
6. Bruera E, MacMillan K, Hanson J, MacDonald RN: The Edmonton staging system for cancer pain: Preliminary report. Pain 1989;37:203-210.
7. Portenoy RK: Opioid tolerance and responsiveness: Research findings and clinical observations; in Gebhart GF, Hammond DL, Jensen TS (eds): Pain Research and Management: Proceedings of the 7th World Congress on Pain. Seattle, I ASP Press, 1994, vol 2, pp 595-614.
8. Hanks GW: The pharmacological treatment of bone pain. Cancer Surv 1988;7:87-100.
9. Kupers RC, Konings H, Adriaensen H, Gybels JM: Morphine differentially affects the sensory and affective pain ratings in neurogenic and ideopathic forms of pain. Pain 1991;47/1:5-12.
10. Arner S, Meyerson BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988;33:11-23.
11. Mercadante S, Maddaloni S, Roccella S, Salvaggio L: Predictive factors in advanced cancer pain treated only by opioids. Pain 1992;50/2:151-155.
12. Galer BS, Coyle N, Pasternak GW, Portenoy RK: Individual variability in the response to different opioids: Report of five cases. Pain 1992;49:87-91.
13. Watson CP, Babul N: Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-1841.
14. Rowbotham MC, Lisa Twilling L, Davies PS, Reisner L, Taylor K, MohrD: Oral Opioid Therapy for Chronic Peripheral and Central Neuropathic Pain. N Engl J Med 2003;348:1223-1232.
15. Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, Royall MR, Max MB: Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebocontrolled trial. Neurology 2002;59:1015-1021.
16. Cherny NI, Thaler HT, Friedlander-Klar H, Lapin J, Foley KM, Houde R, Portenoy RK: Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: A combined analysis of controlled, single-dose studies. Neurology 1994;44:857-861.
17. McQuay HJ, Jadad AR, Carroll D, Faura C, Glynn CJ, Moore RA, Liu Y: Opioid sensitivity of chronic pain: A patient-controlled analgesia method. Anaesthesia 1992;47:757-767.
18. Jadad AR, Carroll D, Glynn CJ, Moore RA, McQuay HJ: Morphine responsiveness of chronic pain: Double-blind randomised crossover study with patient-controlled analgesia. Lancet 1992;339:1367-1371.
19. Benedetti F, Vighetti S, Amanzio M, Casadio C, Oliaro A, Bergamasco B, Maggi G: Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain 1998; 74:205-211.
20. Thomas Z, Bruera E: Use of methadone in a highly tolerant patient receiving parenteral hydromorphone. J Pain Symptom Manage 1995;10:315-317.
21. Sengupta JN, Su X, Gebhart GF: Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Gastroenterology 1996; 111:968-980.
22. Coderre TJ, Katz J, Vaccarino AL, Melzack R: Contribution of central neuroplasticity to pathological pain: Review of clinical and experimental evidence. Pain 1993;52:259-285.
23. Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain. 2. Basic mechanisms that could shift dose-response for analgesia. J Pain Symptom Manage 2001;21:255-264.
24. Ghorpade A, Advokat C: Evidence of a role for NMDA receptors in the facilitation of tail withdrawal after spinal transection. Pharmacol Biochem Behav 1994;48:175-181.
25. Persson J, Axelsson G, Hallin RG, Gustafsson LL: Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. Pain 1995;60:217-222.
26. Mercadante S, Arcuri E, Tirelli W, Casuccio A: Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20:246-252.
27. Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain. 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 2001;21:338-349.
28. Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C: Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol 2001;19:2898-2904.
29. Price DD, Mao J, Lu J, Caruso FS, Frenk H, Mayer DJ: Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats. Pain 1996;68/1:119-127.
30. Bern JL, Peck R: Dextromethorphan: An overview of safety issues. Drug Saf 1992;7:190-199.
31. Gottschalk A, Schroeder F, Ufer M, Oncu A, Buerkle H, Standl T: Amantadine, a N-methyl-D-aspartate receptor antagonist, does not enhance postoperative analgesia in women undergoing abdominal hysterectomy. Anesth Analg 2001;93:192-196.
32. Heiskanen T, Hartel B, Dahl ML, Seppala T, Kalso E: Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain 2002;96:261-267.
33. Santillan R, Maestre JM, Hurle MA, Florez J: Enhancement of opiate analgesia by nimodipine in cancer patients chronically treated with morphine: A preliminary report. Pain 1994;58:129-132.
34. Roca G, Aguilar JL, Gomar C, Mazo V, Costa J, Vidai F: Nimodipine fails to enhance the analgesic effect of slow release morphine in the early phases of cancer pain treatment. Pain 1996;68: 239-243.
35. Puke MJ, Wiesenfeld-Hallin Z: The differential effects of morphine and the alpha 2 adrenoreceptor agonists clonidine and dexmedetomidine on the prevention and treatment of experimental neuropathic pain. Anesth Analg 1993;77:104-109.
36. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D: Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 1995;61:391-399.
37. Stevens C, Yaksh T: Opioid and adrenergic spinal receptor systems and pain control. NIDA Res Monogr 1988;81:343-352.
38. Xu XJ, Puke MJ, Wiesenfeld-Hallin Z: The depressive effect of intrathecal clonidine on the spinal flexor reflex is enhanced after sciatic nerve section in rats. Pain 1992;51:145-152.
39. Levine JD, Gordon NC, TaiwoYO, Coderre TJ: Potentiation of pentazocine analgesia by low-dose naloxone. J Clin Invest 1988;82:1574-1577.
40. Gan TJ, Ginsberg B, Glass PS, Fortney J, Jhaveri R, Perno R: Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 1997;87:1075-1081.
41. Joshi GP, Duffy L, Chehade J, Wesevich J, Gajraj N, Johnson ER: Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Anesthesiology 1999;90:1007-1011.
42. Portenoy RK: Opioid therapy for chronic nonmalignant pain: A review of the critical issues. J Pain Symptom Manage 1996;11:203-217.
43. Portenoy RK: Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 1990;5: S46-S62.
44. Fishbain DA, Rosomoff HL, Rosomoff RS: Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain 1992;8:77-85.
45. Regier DA, Myers JK, Kramer M, Robins LN, Blazer DG, et al: The NIMH Epidemiological Catchment Area Study. Arch Gen Psychiatry 1984;41:934-958.
46. Vailliant G: The Natural History of Alcoholism. Cambridge, Harvard University Press, 1984.
47. Heinemann AW, Keen M, Donohue R, Schnell S: Alcohol use by persons with recent spinal cord injury. Arch Phys Med Rehabil 1988;69:619-624.
48. Honkanen R, Ertama L, Kuosmanen P, Linnoila M, Alha A, Visuri T: The role of alcohol in accidental falls. J Stud Alcohol 1983;44:231-245.
49. Reyna TM, Hollis HW Jr, Hulsebus RC: Alcohol related trauma. The surgeon's responsibility. Ann Surg 1985;201:194-199.
50. Definitions Related to the Use of Opioids for the Treatment of Pain: A consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine, http://www.ampainsoc.org/advocacy/opioids2.htm
51. Brown RL, Rounds LA: Conjoint screening questionnaire for alcohol and drug abuse. Wise Med J 1995;94:135-140.
52. Melzack R: The tragedy of needless pain. Sci Am 1990;262:27-33.
53. Weaver M, Schnoll S: Abuse liability in opioid therapy for pain treatment in patients with an addiction history. Clin J Pain 2002;18:S61-S69.
54. Weissman DE, Haddox JD: Opioid pseudoaddiction: An iatrogenic syndrome. Pain 1989;36: 363-366.
55. Katz N, Fanciullo GJ: Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002;18:S76-S82.
56. Belgrade M: Urine toxicology testing in patients with chronic pain (abstract). American Pain Society Annual Meeting, Phoenix, 2001.
57. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS: Chronic pain-associated depression: Antecedent or consequence of chronic pain? Clin J Pain 1997;13:116-137.
58. Davis PJ, Reeves JL 2nd, Hastie BA, Graff-Radford SB, Naliboff BD: Depression determines illness conviction and pain impact: A structural equation modeling analysis. Pain Med 2000;1: 238-244.
59. Pilowsky I, Chapman CR, Bonica JJ: Pain, depression, and illness behavior in a pain clinic population. Pain 1977;4:183-192.
60. Romano JM, Turner JA: Chronic pain and depression: Does the evidence support a relationship? Psychol Bull 1985;97:18-34.
61. Ahles TA, Khan SA, Yunus MB, Spiegel DA, Masi AT: Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis, and subjects without pain: A blind comparison of DSM-III diagnoses. Am J Psychiatry 1991;148:1721-1726.
62. Haythornthwaite JA, Sieber WJ, Kerns RD: Depression and the chronic pain experience. Pain 1991;46:177-184.
63. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG: Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the US National Comorbidity Survey. Br J Psychiatry Suppl 1996;30:17-30.
64. Banks SM, Kerns RD: Explaining high rates of depression in chronic pain: A diathesis-stress framework. Psychol Bull 1996; 119:95-110.
65. Gamsa A: Is emotional disturbance a precipitator or a consequence of chronic pain? Pain 1990;42:183-195.
66. Gaskin ME, Greene AF, Robinson ME, Geisser ME: Negative affect and the experience of chronic pain. J Psychosom Res 1992;36:707-713.
67. Magni G, Moreschi C, Rigatti-Luchini S, Merskey H: Prospective study on the relationship between depressive symptoms and chronic musculoskeletal pain. Pain 1994;56:289-297.
68. McNairy SL, Maruta T, Ivnik RJ, Swanson DW, Ilstrup DM: Prescription medication dependence and neuropsychologic function. Pain 1984;18:169-177.
69. Ziegler DK: Opiate and opioid use in patients with refractory headache. Cephalalgia 1994; 14:5-10.
70. Ebly EM, Hogan DB, Fung TS: Potential adverse outcomes of psychotropic and narcotic drug use in Canadian seniors. J Clin Epidemiol 1997;50:857-863.
71. Hanks GW, O'Neill WM, Simpson P, Wesnes K: The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepan and placebo in healthy subjects. Eur J Clin Pharmacol 1995;48:455-460.
72. Rapp SE, Egan KJ, Ross BK, Wild LM, Terman GW, Ching JM: A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia. Anesth Analg 1996;82:1043-1048.
73. Zacny JP, Conley K, Marks S: Comparing the subjective, psychomotor and physiological effects of intravenous nalbuphine and morphine in healthy volunteers. J Pharmacol Exp Ther 1997;280: 1159-1169.
74. Moulin DE, lezzi A, Amireh R, Sharpe WKJ, Boyd D, Merskey H: Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996;347:143-147.
75. Tassain Y Attal N, Fletcher D, Brasseur L, Degieux P, Chauvin M, Bouhassira D: Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain. Pain 2003; 104:389-400.
76. Jamison RN, Schein JR, Vallow S, Ascher S, Vorsanger GJ, Katz NP: Neuropsychological effects of long-term opioid use in chronic pain patients. J Pain Symptom Manage 2003;26:913-921.